Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Vincenza Calvaruso, Salvatore Petta, Anna Licata, Ciro Celsa, Vito Di Marco, Calogero Camma', Antonio Craxi, Giuseppe Cabibbo, Giuseppe Alaimo, Francesco Benanti, Gaetano Scifo, Salvatore Madonia, Giovanni Raimondo, Anna Licata, Alfonso Averna, Marco Distefano, Maria Antonietta Di Rosolini, Giovanni Mazzola, Tullio Prestileo, Maria Rita CannavòLicia Larocca, Fabio Cartabellotta, Ignazio Scalisi, Giuseppe Malizia, Irene Cacciola, Maurizio Russello, Gaetano Bertino, Franco Trevisani, Giovanni Squadrito, Bianca Magro, Francesca Rini, Nicola Alessi

Research output: Contribution to journalMeeting Abstract

Abstract

Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation.Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared.Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02).Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.
Original languageEnglish
Number of pages2
JournalDigestive and Liver Disease
Volume51
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients'. Together they form a unique fingerprint.

  • Cite this

    Calvaruso, V., Petta, S., Licata, A., Celsa, C., Di Marco, V., Camma', C., Craxi, A., Cabibbo, G., Alaimo, G., Benanti, F., Scifo, G., Madonia, S., Raimondo, G., Licata, A., Averna, A., Distefano, M., Di Rosolini, M. A., Mazzola, G., Prestileo, T., ... Alessi, N. (2019). Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Digestive and Liver Disease, 51.